Hinckley Allen Representing Royal DSM on $2.6 billion Pharma Transaction

Corporate & Business, Environmental, Litigation, Securities, Securities Litigation


Hinckley Allen is representing Royal DSM, a global life sciences and material sciences company client, in a $2.6 billion series of transactions that will combine Patheon, Inc. (TSX: PTI) and the DSM Pharmaceutical Products business group into a new company to be owned 51% by JLL Partners, a private equity firm,  and 49% by DSM. The combined company will be a leading global contract development and manufacturing company for the pharmaceutical industry.   

Patrick A. Rogers led a team of Hinckley Allen lawyers on the transaction, including James R. Burke, Robin L. Main and David S. Hirsch. The transaction is scheduled to close in the first half of 2014.  See attached press release.

DSM Press Release

We have updated our Privacy Policy. Click here to view changes.